PL1732604T3 - Sposoby leczenia infekcji HIV - Google Patents
Sposoby leczenia infekcji HIVInfo
- Publication number
- PL1732604T3 PL1732604T3 PL05723932T PL05723932T PL1732604T3 PL 1732604 T3 PL1732604 T3 PL 1732604T3 PL 05723932 T PL05723932 T PL 05723932T PL 05723932 T PL05723932 T PL 05723932T PL 1732604 T3 PL1732604 T3 PL 1732604T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- hiv infection
- treating hiv
- treating
- infection
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55576704P | 2004-03-24 | 2004-03-24 | |
| PCT/US2005/006277 WO2005102392A2 (en) | 2004-03-24 | 2005-03-01 | Combinations for treating hiv infection |
| EP05723932A EP1732604B1 (en) | 2004-03-24 | 2005-03-01 | Methods of treating hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1732604T3 true PL1732604T3 (pl) | 2010-12-31 |
Family
ID=34961940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05723932T PL1732604T3 (pl) | 2004-03-24 | 2005-03-01 | Sposoby leczenia infekcji HIV |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7776863B2 (pl) |
| EP (1) | EP1732604B1 (pl) |
| JP (1) | JP4847441B2 (pl) |
| KR (1) | KR101158140B1 (pl) |
| CN (1) | CN1956720B (pl) |
| AR (1) | AR048333A1 (pl) |
| AT (1) | ATE474602T1 (pl) |
| AU (1) | AU2005235116B2 (pl) |
| BR (1) | BRPI0509140A (pl) |
| CA (1) | CA2561146C (pl) |
| CY (1) | CY1111613T1 (pl) |
| DE (1) | DE602005022420D1 (pl) |
| DK (1) | DK1732604T3 (pl) |
| ES (1) | ES2347801T3 (pl) |
| GE (1) | GEP20104925B (pl) |
| HK (1) | HK1096540A1 (pl) |
| HR (1) | HRP20100434T1 (pl) |
| IL (1) | IL178141A (pl) |
| IN (1) | IN2012DN06436A (pl) |
| MY (1) | MY144318A (pl) |
| NO (1) | NO337116B1 (pl) |
| NZ (1) | NZ549778A (pl) |
| PE (1) | PE20060148A1 (pl) |
| PL (1) | PL1732604T3 (pl) |
| PT (1) | PT1732604E (pl) |
| RU (1) | RU2367439C2 (pl) |
| SI (1) | SI1732604T1 (pl) |
| TW (1) | TWI347184B (pl) |
| UA (1) | UA88463C2 (pl) |
| WO (1) | WO2005102392A2 (pl) |
| ZA (1) | ZA200607959B (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US20060100432A1 (en) * | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US20060100209A1 (en) * | 2004-11-09 | 2006-05-11 | Chong-Hui Gu | Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US8318931B2 (en) | 2005-10-28 | 2012-11-27 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
| US8168783B2 (en) | 2005-11-18 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
| US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
| US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| US7501419B2 (en) * | 2006-04-25 | 2009-03-10 | Bristol-Myers Squibb Company | 4-Squarylpiperazine derivatives as antiviral agents |
| US7504399B2 (en) | 2006-06-08 | 2009-03-17 | Bristol-Meyers Squibb Company | Piperazine enamines as antiviral agents |
| US7572810B2 (en) * | 2006-06-08 | 2009-08-11 | Bristol-Myers Squibb Company | Alkene piperidine derivatives as antiviral agents |
| US7960406B2 (en) | 2008-06-25 | 2011-06-14 | Bristol-Myers Squibb Company | Diketo substituted pyrrolo[2,3-c] pyridines |
| WO2009158396A1 (en) * | 2008-06-25 | 2009-12-30 | Bristol-Myers Squibb Company | Diketopiperidine derivatives as hiv attachment inhibitors |
| US20110290821A1 (en) * | 2010-05-28 | 2011-12-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-viral compositions and methods for administration |
| WO2012019003A1 (en) | 2010-08-06 | 2012-02-09 | Bristol-Myers Squibb Company | Substituted indole and azaindole oxoacetyl piperazinamide derivatives |
| WO2012075235A1 (en) | 2010-12-02 | 2012-06-07 | Bristol-Myers Squibb Company | Alkyl amides as hiv attachment inhibitors |
| WO2012106189A1 (en) | 2011-01-31 | 2012-08-09 | Bristol-Myers Squibb Company | Methods of making hiv attachment inhibitor prodrug compound and intermediates |
| US8685982B2 (en) | 2011-04-12 | 2014-04-01 | Bristol-Myers Squibb Company | Thioamide, amidoxime and amidrazone derivatives as HIV attachment inhibitors |
| WO2013033061A1 (en) | 2011-08-29 | 2013-03-07 | Bristol-Myers Squibb Company | Fused bicyclic diamine derivatives as hiv attachment inhibitors |
| US8664213B2 (en) | 2011-08-29 | 2014-03-04 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as HIV attachment inhibitors |
| US9193725B2 (en) | 2012-03-14 | 2015-11-24 | Bristol-Meyers Squibb Company | Cyclic hydrazine derivatives as HIV attachment inhibitors |
| WO2014025854A1 (en) | 2012-08-09 | 2014-02-13 | Bristol-Myers Squibb Company | Piperidine amide derivatives as hiv attachment inhibitors |
| US9655888B2 (en) | 2012-08-09 | 2017-05-23 | VIIV Healthcare UK (No.5) Limited | Tricyclic alkene derivatives as HIV attachment inhibitors |
| CN105283455B (zh) * | 2013-03-27 | 2017-06-16 | 百时美施贵宝公司 | 作为hiv吸附抑制剂的2‑酮基酰胺衍生物 |
| CN107847514A (zh) * | 2015-06-23 | 2018-03-27 | 西托戴恩股份有限公司 | 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变 |
| WO2023172635A1 (en) * | 2022-03-08 | 2023-09-14 | Emory University | Predictive model for variants associated with drug resistance and theranostic applications thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2322868C (en) * | 1998-03-02 | 2009-02-03 | The University Of North Carolina At Chapel Hill | Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| US6476034B2 (en) | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| KR20040065251A (ko) * | 2001-12-12 | 2004-07-21 | 브리스톨-마이어스 스큅 컴퍼니 | Ｈｉｖ 인티그레이즈 억제제 |
| EP1465889B1 (en) * | 2001-12-21 | 2017-03-22 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
-
2005
- 2005-02-24 US US11/064,683 patent/US7776863B2/en active Active
- 2005-03-01 RU RU2006137555/14A patent/RU2367439C2/ru active
- 2005-03-01 JP JP2007504971A patent/JP4847441B2/ja active Active
- 2005-03-01 CA CA2561146A patent/CA2561146C/en active Active
- 2005-03-01 PT PT05723932T patent/PT1732604E/pt unknown
- 2005-03-01 UA UAA200611163A patent/UA88463C2/ru unknown
- 2005-03-01 WO PCT/US2005/006277 patent/WO2005102392A2/en active Application Filing
- 2005-03-01 SI SI200531100T patent/SI1732604T1/sl unknown
- 2005-03-01 DE DE602005022420T patent/DE602005022420D1/de active Active
- 2005-03-01 GE GEAP20059667A patent/GEP20104925B/en unknown
- 2005-03-01 DK DK05723932.9T patent/DK1732604T3/da active
- 2005-03-01 IN IN6436DEN2012 patent/IN2012DN06436A/en unknown
- 2005-03-01 AT AT05723932T patent/ATE474602T1/de active
- 2005-03-01 ES ES05723932T patent/ES2347801T3/es active Active
- 2005-03-01 KR KR1020067019595A patent/KR101158140B1/ko active IP Right Grant
- 2005-03-01 BR BRPI0509140-3A patent/BRPI0509140A/pt not_active Application Discontinuation
- 2005-03-01 CN CN2005800160669A patent/CN1956720B/zh active Active
- 2005-03-01 EP EP05723932A patent/EP1732604B1/en active Active
- 2005-03-01 AU AU2005235116A patent/AU2005235116B2/en active Active
- 2005-03-01 PL PL05723932T patent/PL1732604T3/pl unknown
- 2005-03-01 NZ NZ549778A patent/NZ549778A/en unknown
- 2005-03-17 MY MYPI20051136A patent/MY144318A/en unknown
- 2005-03-18 TW TW094108462A patent/TWI347184B/zh active
- 2005-03-23 AR ARP050101159A patent/AR048333A1/es active Pending
- 2005-03-28 PE PE2005000344A patent/PE20060148A1/es not_active Application Discontinuation
-
2006
- 2006-09-17 IL IL178141A patent/IL178141A/en active IP Right Review Request
- 2006-09-22 ZA ZA200607959A patent/ZA200607959B/en unknown
- 2006-10-06 NO NO20064547A patent/NO337116B1/no unknown
-
2007
- 2007-04-20 HK HK07104156.5A patent/HK1096540A1/xx unknown
-
2010
- 2010-08-03 HR HR20100434T patent/HRP20100434T1/hr unknown
- 2010-10-20 CY CY20101100937T patent/CY1111613T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI347184B (en) | Methods of treating hiv infection | |
| EP1753777A4 (en) | METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING HIV INFECTION WITH TRIM5a | |
| IL207575A0 (en) | Vaccine for prevention and treatment of hiv infection | |
| EP1755584A4 (en) | TREATMENT OF MYOPIA | |
| IL178996A0 (en) | Thienopyridinone compounds and methods of treatment | |
| IL182436A0 (en) | Thienopyridinone compounds and methods of treatment | |
| GB0329254D0 (en) | Treatment of viral infections | |
| IL182993A0 (en) | Treatment of mastitis | |
| EP1827475A4 (en) | METHOD FOR TREATING HIV INFECTION | |
| ZA200806505B (en) | Treatment of HIV | |
| GB0422439D0 (en) | Inhibitors of infection | |
| EP1660116A4 (en) | METHOD FOR THE TREATMENT OF VIRUS INFECTIONS | |
| GB2441094B (en) | Methods for treatment and prevention of infection | |
| GB0329958D0 (en) | Treatment of viral infections | |
| GB0415181D0 (en) | Compounds for use in the treatment of infection | |
| GB0504333D0 (en) | Treatment of cytokine dysregulation | |
| GB0426196D0 (en) | Methods of treatment | |
| EP1691776A4 (en) | TREATMENT OF AIDS | |
| ZA200702654B (en) | Treatment of HIV infection by T-cell modulation | |
| GB0327975D0 (en) | Methods of treatment | |
| GB0422012D0 (en) | Methods of treatment | |
| HU0400952D0 (en) | Treatment of anus-cancer | |
| GB201010682D0 (en) | Methods for treatment and prevention of infection | |
| GB0510257D0 (en) | Methods for treatment and prevention of infection | |
| IL187889A0 (en) | Compositions and methods for preventing or treating hiv infection |